Deerland Probiotics & Enzymes’ Probiotic DE111® First Bacillus subtilis to Attain Notified Food-Health Relationship Claims in Australia and New Zealand

Deerland Probiotics & Enzymes, a global supplier of science-backed solutions for microbiome health, is pleased to announce that its probiotic Bacillus subtilis DE111® has attained a list of published health claims in relationship to its inclusion as a food ingredient under the Food Standards Australia New Zealand (FSANZ) Code.

Companies seeking to make a general level health claim for a food ingredient in Australia and New Zealand must perform a comprehensive and systematic review of evidence of a causal food-health relationship. Deerland was able to conduct this assessment of the probiotic DE111 based on the wealth of peer-reviewed clinical publications on the strain. As a result, DE111 is now the first Bacillus subtilis probiotic to have food-health supported claims associated with its use in Australia and New Zealand food products.

The claims include “promotes growth of healthy gastrointestinal flora”, “supports growth of beneficial gut bacteria”, “supports and improves digestive health in children and adults”, and “reduces total blood cholesterol or blood LDL cholesterol”.

“DE111 provides unique, specific claims and connects consumers’ growing interest in self-care with products that can deliver on their needs,” said Simon Lord, Deerland’s director of sales for Australia and New Zealand.

Steen Andersen, president of Deerland International, added, “This opens up many opportunities for brands to meet the growing demand for probiotic products in Australia and New Zealand by enhancing their food and beverages with functionality, communicated through science-backed claims.”

In addition to the published notification of claims, DE111 has received a letter of no-objection on its GRAS status from USFDA, non-Novel Food status in both Canada and Australia, as well as approval as a natural health ingredient by Health Canada. Further, DE111 is Star-K Kosher certified and Non-GMO Project verified.

New Study: Probiotic Bacillus subtilis DE111® Shown to Support Immune Health

Deerland Probiotics & Enzymes has announced the publication of a new clinical study examining the immune support effects of Bacillus subtilis DE111®.

The study, “Examining the Gastrointestinal and Immunomodulatory Effects of the Novel Probiotic Bacillus subtilis DE111” published in the International Journal of Molecular Sciences, is an IRB-approved, randomized, double-blind, placebo-controlled study involving 44 healthy adults (aged 20 to 62). Participants consumed either B. subtilis DE111® (1 billion CFU) or placebo daily for four weeks. The researchers examined peripheral blood mononuclear cells (PBMCs) at basal levels pre- and post-study, as well as in response to stimulation with bacterial lipopolysaccharide (LPS), which encourages neutrophils, macrophages and other innate immune cells to release pro-inflammatory cytokines. The results of the study indicated that DE111 can support a healthy immune system and a robust immune response.

After only four weeks of supplementing with DE111, the authors found, participants displayed immunomodulatory and anti-inflammatory effects on several T cell subsets. “This is supported by the observed reduction in immune cell populations within the basal state,” they write. “The downregulation of these cell types in circulation may implicate an overall anti-inflammatory state demonstrated by the decrease in peripheral surveillance and effector cell types.” Another proposed mechanism suggests that DE111 ingestion improved the gut barrier function resulting in less circulating LPS, thereby reducing inflammation levels. In addition, the authors found those in the DE111 group exhibited an increase in anti-inflammatory immune cell populations in response to ex vivo LPS stimulation of PBMCs, which is indicative of a more robust response to prime the immune system. In summary, they explained, this study shows supplementing with B. subtilis DE111 “modulates the host immune system through anti-inflammatory and suppressive action on both innate and adaptive cell types.”

“This newly published study substantiates the efficacy of B. subtilis DE111® for use in products that address the most common concerns of the day– a strong immune system with a quick response to foreign invaders,” said Dr. John Deaton, vice president of science and technology at Deerland Probiotics & Enzymes. “The latest publication adds to an impressive list of clinical studies showing DE111’s impact on digestive, children’s and cardio health and sports performance/recovery,” Deaton adds.

Deerland Probiotics & Enzymes Launches New Company Tagline – “Motivated by science, measured by wellness.”

Deerland Probiotics & Enzymes is pleased to unveil the company’s new global brand tagline– “Motivated by science, measured by wellness.” The tagline is intended to better align Deerland’s brand identity with its vision “for all people of all cultures to benefit from its enzyme, probiotic and prebiotic health products”, along with its mission “to measurably improve the quality of people’s lives by creating innovative, scientifically sound products, services, and technology.”

Since joining the company as CEO in 2008, Scott Ravech has led Deerland in a consistent progression from strictly an ingredient supplier and contract manufacturer to an innovative solutions partner in the health and nutrition industry–marked by investments in talent, manufacturing capabilities, quality certifications, R&D and clinical science. “Change is inevitable and Deerland’s success, in many ways, has been driven by its willingness to evolve and continually improve,” Ravech said. He added, “While our previous tagline has served us very well for many years, our customers should rest assured that all the value we have provided until now will not change. This new tag better reflects the expanded portfolio of products, services, capabilities and science we are able to offer our valued customers.”

Deerland’s previously existing brand tagline, “From concept to commercialization, we add value at every step” will be replaced by the new one in the first quarter of 2021 with a full-scale launch.

Deerland Probiotics & Enzymes Hires New Business Development Manager for the Southern US Region

Deerland Probiotics and Enzymes, a global supplier of science-backed solutions for microbiome health, has announced the hiring of Arthur Radcliffe as the company’s business development manager responsible for the southern United States.

Radcliffe brings more than 25 years of industry experience with Lonza-Capsugel, holding various expanded positions in sales and marketing, most recently as business development manager in the midwest & southeast regions. Operating from Greenwood, SC, he will now represent Deerland’s business development initiatives working with customers across the southern states.

Radcliffe joins the team of business development managers in the Americas led by Michelle Cook, who joined Deerland as vice president of sales for the region in November of 2020. “We’re excited to welcome Arthur to the Deerland team,” said Cook. “The depth and breadth of his industry knowledge is certain to benefit our valued customers and partners.”

New Study: Probiotic DE111® Shown to Support GI Health and Immunity in Daycare-Attending Children

Deerland Probiotics and Enzymes has announced the publication of a clinical study showing that the administration of the probiotic Bacillus subtilis DE111® can support gastrointestinal function in preschool-aged children.

The study, “Effect of Daily Bacillus subtilis DE111® Intake on Gastrointestinal Health and Respiratory Infections in Children Attending Day-care” published in the Journal of Probiotics and Health, is an IRB-approved, randomized, double-blind, placebo-controlled trial involving 81 children aged 2 to 6. The researchers analyzed the incidence and duration of symptoms of gastrointestinal and respiratory infections after eight weeks and then again after four weeks post-termination.

Results of the study showed that daily consumption of the probiotic strain Bacillus subtilis DE111 (1 billion CFU) supported a healthy gastrointestinal tract with a reduced duration of vomiting, hard stools and overall gastrointestinal discomfort.

Specifically, results in the probiotic group showed a statistically significant reduction in vomiting duration – 2 days in the probiotic group versus 14 days in the placebo group, and significant reduction in duration of hard stools – 0 days in the probiotic group versus 15 days in the placebo group. In the case of overall gastrointestinal discomfort, those children in the probiotic group had a significantly lower 18 days of discomfort while those in the placebo group had 48 days. Additionally, a strong trend was observed in the lowering of gastrointestinal infection incidences – 7.1% in the DE111® group versus 20.5% in the placebo group; as well as a reduction of GI infection durations – 8 days in the DE111® group versus 28 days in the placebo group.

The researchers concluded that, based on the distinctions between the two groups, “Supplementing with B. subtilis DE111® supports a healthy gastrointestinal tract with a reduced duration of vomiting, hard stools and overall gastrointestinal discomfort. Furthermore, B. subtilis DE111® was shown to be safe for use in children aged 2-6 years old.”

“This is highly encouraging research showing that supplementation with the probiotic DE111 can help support the health of young children in preschool, via the gastrointestinal system,” said John Deaton, vice president of science and technology at Deerland.

New Study: Probiotic DE111® Shown to Promote a Healthy Microbiome for Immune Support in Daycare-Attending Children

Deerland Probiotics and Enzymes has announced the publication of a clinical study showing that the administration of the probiotic Bacillus subtilis DE111® can modify the composition of the microbiome in preschool-aged children.

The study, “Daily intake of probiotic strain Bacillus subtilis DE111 supports a healthy microbiome in children attending day-care” published in Beneficial Microbes, is an IRB-approved, randomized, double-blind, placebo-controlled trial involving 91 children aged 2 to 6. Results of the study showed that daily consumption of the probiotic strain Bacillus subtilis DE111 positively modulated the gut microbiome profile without changing the overall microbiome equilibrium.

After 8 weeks of daily probiotic consumption, the researchers observed an increase in alpha-diversity at the phylum level, suggesting an expanded functional diversity of the microbiome compared to that of the children in the placebo group. Specifically, there were 9 differentially abundant taxa at the genus level found in the probiotic group, six (of the phylum bacteroidetes) grew in abundance while three (of the phylum firmicutes) were reduced. The six taxa of bacteroidetes that flourished are involved in immune regulation and reduction of inflammation. This modulation of the firmicutes/bacteroidetes ratio of the microbiome in children taking B. subtilis DE111 is a positive indication for healthy gut function.

Overall, according to the researchers, these results suggest B. subtilis DE111 supports the maintenance of a healthy gut through subtle modulations of the microbiome with significant benefits in preschool aged children.

“On the dawn of a new highly modified school year where health takes center stage, this study is highly encouraging to formulate natural, safe products for young children to promote immunity and overall well-being so they can concentrate on learning,” said John Deaton, vice president of science and technology at Deerland. “Focusing on supporting a healthy microbiome will result in more robust and effective immunity as children get older.”

Clinical Study: Probiotic DE111® Shown to Promote a Healthy Microbiome for Immune Support in Daycare-Attending Children

Deerland Probiotics and Enzymes has announced the publication of a clinical study showing that the administration of the probiotic Bacillus subtilis DE111® can modify the composition of the microbiome in preschool-aged children.

The study, “Daily intake of probiotic strain Bacillus subtilis DE111 supports a healthy microbiome in children attending day-care” published in Beneficial Microbes, is an IRB-approved, randomized, double-blind, placebo-controlled four-week trial involving 91 children aged 2 to 6. Results of the study showed that daily consumption of the probiotic strain Bacillus subtilis DE111 positively modulated the gut microbiome profile without changing the overall microbiome equilibrium.

After 8 weeks of daily probiotic consumption, the researchers observed an increase in alpha-diversity at the phylum level, suggesting an expanded functional diversity of the microbiome compared to that of the children in the placebo group. Specifically, there were 9 differentially abundant taxa at the genus level found in the probiotic group, six (of the phylum bacteroidetes) grew in abundance while three (of the phylum firmicutes) were reduced. The six taxa of bacteroidetes that flourished are involved in immune regulation and reduction of inflammation. This modulation of the firmicutes/bacteroidetes ratio of the microbiome in children taking B. subtilis DE111 is a positive indication for healthy gut function.

Overall, according to the researchers, these results suggest B. subtilis DE111 supports the maintenance of a healthy gut through subtle modulations of the microbiome with significant benefits in preschool aged children.

“On the dawn of a new highly modified school year where health takes center stage, this study is highly encouraging to formulate natural, safe products for young children to promote immunity and overall well-being so they can concentrate on learning,” said John Deaton, vice president of science and technology at Deerland. “Focusing on supporting a healthy microbiome will result in more robust and effective immunity as children get older.”

Family First™: The Gift of Hope for the Holidays

Founded in 1989 by a group of employees of the former National Enzyme who wanted to sponsor a family in need for the holidays, Gift of Hope has grown into a non-profit organization providing essentials and pathways to independence for families in Taney County, Missouri. The group accomplishes this work through various programs, including the Backpack Club, Scholarships, and Christmas Share.

The mission of Gift of Hope’s Christmas Share Program is to assist families living in Taney County throughout the winter months, when financial hardship tends to be most prevalent, particularly due to the seasonal work cycle of the tourism-driven community. The program helps pay bills for rent, propane, and electricity. And each year during the holiday season, the Gift of Hope organization adopts several families that could use some extra help to provide presents for their children. Volunteers always enjoy meeting with each family and taking them shopping for essentials and gifts.

“I was recently contacted by one of our families that we assisted last Christmas,” said Jennifer Costello, the director of the Gift of Hope organization. The father of the family shared that they were so grateful for the help they had received last year that they wanted to give back and “pay it forward”, because they were thankfully in a much better place financially this year. He now wants to donate a few hundred dollars back to our Christmas Share program so that another family can be blessed this year just like his family was last Christmas.

“We don’t always hear back from a lot of our families, so when we do, it is heartwarming to see how much of an impact we are making on the lives of those that we touch every year,” Jennifer said.

Deerland is proud to put Family First through its support of the Gift of Hope organization. We’d like to thank everyone that continues to support this worthy cause; we truly appreciate you and want you to know the difference that you are making in the lives of so many children and families.

To support the families of Taney County, Missouri through Gift of Hope, visit https://giftofhopeinc.org/donate/.

Deerland Probiotics & Enzymes Hires Vice President of Sales-Americas, Expands Executive Team

Deerland Probiotics and Enzymes has announced the hiring of a new vice president of sales-Americas as well as the creation of a new executive level position for product development and supply chain.

Michelle Cook has been named the company’s vice president of sales for the Americas region. Cook brings more than 25 years of experience leading sales teams in the OTC pharmaceutical and dietary supplement industries, most recently with DuPont Nutrition & Biosciences. She will oversee Deerland’s team of business development managers as they serve customers across the dietary supplement, food and beverage and pet nutrition industries.

With the addition of Michelle Cook as vice president of sales, Tod Burgess, who previously held the position for more than 20 years, has moved into the newly created role of vice president of product development and supply chain. In this role, Burgess’s expertise will be harnessed to optimize the up-front product development process and supply chain continuity.

Scott Ravech, CEO, comments, “The addition of Michelle Cook to our staff along with Tod’s new role as vice president of product development and supply chain position demonstrates Deerland’s commitment to placing the best people in critical roles in order to provide maximum value for our customers.”

Deerland Probiotics & Enzymes, based in Kennesaw, Ga., specializes in developing science-backed solutions that benefit microbiome health, using probiotic, prebiotic and enzyme technology. The company offers a line of unique, clinically validated branded products, including DE111®, PreforPro®, ProHydrolase®, Solarplast®, Glutalytic® and Bifolac® probiotic strains. Deerland collaborates with customers to develop innovative and often proprietary solutions in the dietary supplement, food and beverage, sports nutrition, and companion animal markets. In addition to branded ingredients and customized formulations, Deerland offers full turnkey products for private label through its YourBrand® portfolio. The company’s manufacturing services include bulk blends, capsules, stick packs and tablets, as well as bottling and labeling. To contact Deerland Probiotics & Enzymes, call 800.697.8179 or visit www.deerland.com.

New Study: Probiotic DE111® Found to Support Cardiovascular Health

Deerland Probiotics and Enzymes has announced the publication of a clinical study demonstrating efficacy of the probiotic Bacillus subtilis DE111® in promoting healthy endothelial function and support of healthy cholesterol levels.

The study, “Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults” published in Beneficial Microbes, was performed at a leading university specializing in probiotics research and is an IRB-approved, randomized, double-blind, placebo-controlled four-week trial involving 43 participants aged 18 to 65.

The overall goal of this parallel arm trial was to determine if various cardiovascular parameters in healthy adults could be altered by probiotic supplementation. This new research was based on findings from previous studies that showed clear correlations between certain probiotic strains and healthy vascular function, reduced systemic inflammation and glucose tolerance, as well as evidence that the species Bacillus subtilis can support healthy cholesterol levels with positive cardiovascular effects in animal models.

The research team found that B. subtilis DE111 supplementation of 1 billion CFU per day resulted in significant reduction in total cholesterol and non-HDL cholesterol relative to baseline measures. The team also observed a strong trend toward reduction in LDL cholesterol, as well as improvement in endothelial function; reactive hyperemia index (RHI), an indicator of blood flow and heart health, increased by 9.14%.

“To our knowledge, this is the first randomized controlled trial to investigate the effects of B. subtilis supplementation on these parameters in a human population,” the principal investigators of the study stated. The authors of the study believe that B. subtilis supplementation may have an indirect effect on enhancing the generation of short chain fatty acids (SCFA) leading to this cholesterol lowering effect.

“Notably, these effects were observed in a population of healthy individuals, and the results strongly suggest that B. subtilis supplementation may help support cardiovascular health,” commented Dr. John Deaton, vice president of science and technology at Deerland.

Deaton added that the spore-forming properties of the probiotic DE111® allow formulating in a wide array of attractive consumer products even beyond traditional supplement capsules, including gummies, chocolates, functional beverages and fitness nutrition powders.

Clinical Study: Probiotic DE111® Found to Support Cardiovascular Health

Deerland Probiotics and Enzymes has announced the publication of a clinical study demonstrating efficacy of the probiotic Bacillus subtilis DE111® in promoting healthy endothelial function and support of healthy cholesterol levels.

The study, “Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults” published in Beneficial Microbes, was performed at a leading university specializing in probiotics research and is an IRB-approved, randomized, double-blind, placebo-controlled four-week trial involving 43 participants aged 18 to 65.

The overall goal of this parallel arm trial was to determine if various cardiovascular parameters in healthy adults could be altered by probiotic supplementation. This new research was based on findings from previous studies that showed clear correlations between certain probiotic strains and healthy vascular function, reduced systemic inflammation and glucose tolerance, as well as evidence that the species Bacillus subtilis can support healthy cholesterol levels with positive cardiovascular effects in animal models.

The research team found that B. subtilis DE111 supplementation of 1 billion CFU per day resulted in significant reduction in total cholesterol and non-HDL cholesterol relative to baseline measures. The team also observed a strong trend toward reduction in LDL cholesterol, as well as improvement in endothelial function; reactive hyperemia index (RHI), an indicator of blood flow and heart health, increased by 9.14%.

“To our knowledge, this is the first randomized controlled trial to investigate the effects of B. subtilis supplementation on these parameters in a human population,” the principal investigators of the study stated. The authors of the study believe that B. subtilis supplementation may have an indirect effect on enhancing the generation of short chain fatty acids (SCFA) leading to this cholesterol lowering effect.

“Notably, these effects were observed in a population of healthy individuals, and the results strongly suggest that B. subtilis supplementation may help support cardiovascular health,” commented Dr. John Deaton, vice president of science and technology at Deerland.

Deaton added that the spore-forming properties of the probiotic DE111® allow formulating in a wide array of attractive consumer products even beyond traditional supplement capsules, including gummies, chocolates, functional beverages and fitness nutrition powders.

New Study: Prebiotic PreforPro® Shows Synbiotic Benefits for GI Function

Deerland Probiotics and Enzymes has announced the publication of a human clinical trial demonstrating the synbiotic benefits of PreforPro®, a unique and proprietary blend of bacteriophages, in promoting the balance of good bacteria in the microbiome.

The goal of the parallel-arm study was to investigate whether adding bacteriophages with a probiotic would provide additional benefits to gastrointestinal function as well as augment the microbiota in the gut compared to the probiotic by itself, suggesting a truly synergistic capability.

The study, “PHAGE-2 Study: Supplemental Bacteriophages Extend Bifidobacterium animalis subsp. lactis BL04 Benefits on Gut Health and Microbiota”, published in Nutrients, was a randomized, double-blind, placebo-controlled clinical intervention trial. In this study, 66 participants were randomly assigned to one of three groups: placebo; Bifidobacterium animalis BL04 (B. lactis BL04) 1 billion CFU; or B. lactis BL04 (1 billion CFU) plus PreforPro (15mg). Participants consumed one capsule per day for four weeks. The outcomes sought were impacts on GI discomfort as well as changes or modulation of the gut microbiota.

Overall, the researchers found that the individuals in the B. lactis plus PreforPro group showed the following:

  • Improvements in self-reported GI inflammation symptoms
  • Reduction in colonic cramp discomfort
  • Greater increase in the presence of Lactobacillus vs. placebo
  • Decrease of strains Citrobacter and Desulfovibrio, which are associated with gut inflammation and GI disorders
  • Reduction in E. coli

In conclusion, the study demonstrates that supplementing B. lactis BL04 with PreforPro can significantly modulate gut ecology to favor beneficial bacteria. “In addition, a lack of global changes to the microbiota (dysbiosis) in combination with specific modulation of certain taxa, like Lactobacillus, suggests that PreforPro displays prebiotic-like effects and may extend the GI benefits of consuming B. lactis or other probiotics.,” says John Deaton, vice president of science and technology for Deerland Probiotics & Enzymes.

“This study demonstrates the opportunity and capability of phages in the robust support of healthy microflora balance and the associated physiological benefits. Phages are clearly up-and-coming supplements in the rapidly burgeoning arena of microbiome support.”